{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:43Z","timestamp":1791546643071,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"JSPS","doi-asserted-by":"publisher","award":["24\u00a0K108-99"],"award-info":[{"award-number":["24\u00a0K108-99"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The purpose of the present study is to confirm the efficacy and feasibility of moderately hypofractionated proton beam therapy (PBT) at a total dose of 63\u00a0Gy relative biological effectiveness (RBE) in 21 fractions for prostate cancer. This phase II clinical trial (PPS-002: UMIN 000017679) enrolled 125 men with histologically confirmed prostate cancer (cT1c-3aN0M0). The primary endpoint was grade\u2009\u22652 late gastrointestinal (GI) toxicities. Secondary endpoints included biochemical recurrence rates, clinical recurrence rates, overall survival (OS) and acute toxicities and late genitourinary (GU) toxicities. With a median follow-up period of 71.0\u00a0months (IQR: 60\u201384), the 5-year cumulative incidences of late grade 2 or higher GI and GU adverse events (AEs) were 3.3% and 8.1%, respectively. Biochemical recurrences were observed in three patients; no clinical recurrences occurred. The 5-year biochemical recurrence-free, clinical recurrence-free and OS rates were 97.6% (95% CI: 94.9\u2013100.0), 100% and 97.5% (95% CI: 94.8\u2013100.0), respectively. The long-term follow-up results of moderately hypofractionated PBT of 63\u00a0Gy (RBE) in 21 fractions confirmed low incidences of late AEs, successfully meeting the primary endpoint. Furthermore, the low incidence of tumor recurrence supports the overall safety and feasibility of this fractionation schedule.<\/jats:p>","DOI":"10.1093\/jrr\/rrag051","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:30:13Z","timestamp":1784633413000},"page":"779-786","source":"Crossref","is-referenced-by-count":0,"title":["Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-4356","authenticated-orcid":false,"given":"Takashi","family":"Iizumi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-9787","authenticated-orcid":false,"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]},{"name":"QST Hospital, National Institutes for Quantum Science and Technology , 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]},{"name":"Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, 6528 Koibuchi, Kasama, \u00a0 Ibaraki 309-1793 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tsuchiura Kyodo General Hospital , 4-1-1, Otsuno, Tsuchiura, Ibaraki 300-0028 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hitachi General Hospital, Hitachi Ltd. , 2-1-1 Jonancho, Hitachi, Ibaraki 317-0077 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Makishima","sequence":"additional","affiliation":[{"name":"QST Hospital, National Institutes for Quantum Science and Technology , 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamizawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-1301","authenticated-orcid":false,"given":"Masashi","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, 6528 Koibuchi, Kasama, \u00a0 Ibaraki 309-1793 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Toho University Sakura Medical Center , 564-1 Shimoshizu, Sakura, Chiba 263-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine and Graduate School of Comprehensive Human Science, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]},{"name":"Center for Cyber Medicine Research, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-8639","authenticated-orcid":false,"given":"Hideyuki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba , 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026100906565249100_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026100906565249100_ref2","volume-title":"Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare) (Last Access on February 24th, 2026)","author":"Cancer statistics"},{"key":"2026100906565249100_ref3","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.3390\/cancers14246076","article-title":"Long-term projections of cancer incidence and mortality in Japan and decomposition analysis of changes in cancer burden, 2020-2054: an empirical validation approach","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026100906565249100_ref4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100906565249100_ref5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jjco\/hyw102","article-title":"Proton beam therapy in Japan: current and future status","volume":"46","author":"Sakurai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"2026100906565249100_ref6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ijrobp.2007.07.2335","article-title":"Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer","volume":"70","author":"Vargas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100906565249100_ref7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026100906565249100_ref8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026100906565249100_ref9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026100906565249100_ref10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026100906565249100_ref11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"2026100906565249100_ref12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jrr\/rrae026","article-title":"Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial","volume":"65","author":"Murakami","year":"2024","journal-title":"J Radiat Res"},{"key":"2026100906565249100_ref13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jmrs.551","article-title":"Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer","volume":"69","author":"Iizumi","year":"2022","journal-title":"J Med Radiat Sci"},{"key":"2026100906565249100_ref14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3892\/mco.2017.1372","article-title":"A retrospective study of late adverse events in proton beam therapy for prostate cancer","volume":"7","author":"Makishima","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2026100906565249100_ref15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100906565249100_ref16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/cam4.1350","article-title":"Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group","volume":"7","author":"Iwata","year":"2018","journal-title":"Cancer Med"},{"key":"2026100906565249100_ref17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.ijrobp.2020.11.007","article-title":"Proton therapy for localized prostate cancer: long-term results from a single-center experience","volume":"109","author":"Takagi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100906565249100_ref18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10147-017-1209-8","article-title":"Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer","volume":"23","author":"Nakajima","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2026100906565249100_ref19","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1016\/j.prro.2023.06.004","article-title":"Long-term outcomes of a prospective study on highly hypofractionated intensity modulated radiation therapy for localized prostate cancer for 3 weeks","volume":"13","author":"Nakamura","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"2026100906565249100_ref20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12885-020-6570-8","article-title":"Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study ``GUNMA0702''","volume":"20","author":"Kawamura","year":"2020","journal-title":"BMC Cancer"},{"key":"2026100906565249100_ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14338\/IJPT-19-00057","article-title":"Hypofractionated proton therapy in early prostate cancer: results of a phase I\/II trial at Loma Linda University","volume":"6","author":"Slater","year":"2019","journal-title":"Int J Part Ther"},{"key":"2026100906565249100_ref22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S0360-3016(01)01704-7","article-title":"Argon plasma coagulation for rectal bleeding after prostate brachytherapy","volume":"51","author":"Smith","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026100906565249100_ref23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.gie.2025.07.001","article-title":"Risk factors of bleeding ulceration after argon plasma coagulation in patients with radiation-associated vascular ectasias","volume":"103","author":"Pattarajierapan","year":"2025","journal-title":"Gastrointest Endosc"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/5\/779\/69887655\/rrag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/5\/779\/69887655\/rrag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:57:00Z","timestamp":1791543420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/67\/5\/779\/8740783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrag051","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,23]]}}}